HUTCHMED (China) Limited Asset Resilience Ratio
HUTCHMED (China) Limited asset resilience ratio. HUTCHMED (China) Limited (H7T1) has an Asset Resilience Ratio of 73.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can HUTCHMED (China) Limited fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of HUTCHMED (China) Limited (2016–2025)
Asset resilience ratio of HUTCHMED (China) Limited from 2016 to 2025. This chart shows how HUTCHMED (China) Limited's Asset Resilience Ratio has changed over time. Read H7T1 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down HUTCHMED (China) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of HUTCHMED (China) Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.30 Billion | 73.92% |
| Total Liquid Assets | €1.30 Billion | 73.92% |
Asset Resilience Insights
- Very High Liquidity: HUTCHMED (China) Limited maintains exceptional liquid asset reserves at 73.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
HUTCHMED (China) Limited Industry Peers by Asset Resilience Ratio
Compare HUTCHMED (China) Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
HUTCHMED (China) Limited Asset Resilience Ratio by Year (2016–2025)
HUTCHMED (China) Limited asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for HUTCHMED (China) Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.92% | €1.30 Billion ≈ $1.52 Billion |
€1.75 Billion ≈ $2.05 Billion |
+20.39pp |
| 2024-12-31 | 53.54% | €682.15 Million ≈ $797.51 Million |
€1.27 Billion ≈ $1.49 Billion |
+6.44pp |
| 2023-12-31 | 47.10% | €602.75 Million ≈ $704.67 Million |
€1.28 Billion ≈ $1.50 Billion |
+16.23pp |
| 2022-12-31 | 30.86% | €317.72 Million ≈ $371.45 Million |
€1.03 Billion ≈ $1.20 Billion |
-15.34pp |
| 2021-12-31 | 46.20% | €634.16 Million ≈ $741.40 Million |
€1.37 Billion ≈ $1.60 Billion |
+18.64pp |
| 2020-12-31 | 27.56% | €199.55 Million ≈ $233.29 Million |
€724.12 Million ≈ $846.57 Million |
+6.91pp |
| 2019-12-31 | 20.64% | €96.01 Million ≈ $112.25 Million |
€465.12 Million ≈ $543.78 Million |
-19.75pp |
| 2018-12-31 | 40.39% | €214.91 Million ≈ $251.26 Million |
€532.12 Million ≈ $622.10 Million |
-5.27pp |
| 2017-12-31 | 45.66% | €273.03 Million ≈ $319.20 Million |
€597.93 Million ≈ $699.05 Million |
+38.58pp |
| 2016-12-31 | 7.09% | €24.27 Million ≈ $28.37 Million |
€342.44 Million ≈ $400.34 Million |
-- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more